Hereditary Cancer in Clinical Practice最新文献

筛选
英文 中文
Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline. BRCA1/2 遗传性卵巢癌综合征的风险降低策略:临床实践指南。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-09-26 DOI: 10.1186/s13053-021-00196-9
Michelle Jacobson, Nadia Coakley, Marcus Bernardini, Kelly-Ann Branco, Laurie Elit, Sarah Ferguson, Raymond Kim
{"title":"Risk reduction strategies for BRCA1/2 hereditary ovarian cancer syndromes: a clinical practice guideline.","authors":"Michelle Jacobson, Nadia Coakley, Marcus Bernardini, Kelly-Ann Branco, Laurie Elit, Sarah Ferguson, Raymond Kim","doi":"10.1186/s13053-021-00196-9","DOIUrl":"10.1186/s13053-021-00196-9","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this guideline is to make recommendations regarding the care of women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2.</p><p><strong>Methods: </strong>Draft recommendations were formulated based on evidence obtained through a systematic review of RCTs, comparative retrospective studies and guideline endorsement. The draft recommendations underwent an internal review by clinical and methodology experts, and an external review by clinical practitioners.</p><p><strong>Results: </strong>The literature search yielded 1 guideline, 5 systematic reviews, and 15 studies that met the eligibility criteria.</p><p><strong>Conclusions: </strong>In women who harbour a pathogenic or likely pathogenic variant in BRCA1 and BRCA2 screening for ovarian cancer is not recommended. Risk-reducing surgery is recommended to reduce the risk of ovarian cancer. In the absence of contraindications, premenopausal women undergoing RRSO should be offered hormone therapy until menopause. Systemic hormone replacement therapy, is not recommended for women who have had a personal history of breast cancer. RRSO should be considered for breast cancer risk reduction in women younger than 50 years. After a breast cancer diagnosis, RRSO for breast cancer mortality reduction can be considered within two years to women who harbour a pathogenic or likely pathogenic variant in BRCA1 if younger than the recommended age range for ovarian cancer risk reduction. RRSO before the age of 40 and specifically for breast cancer treatment in BRCA2 should be considered only if recommended by their breast cancer oncologist. Following RRSO, it is not recommended to do surveillance for peritoneal cancer.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"39"},"PeriodicalIF":1.7,"publicationDate":"2021-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39450723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report. 利用患者同伴支持改进我们的遗传性癌症风险级联检测模式:概念报告。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-09-26 DOI: 10.1186/s13053-021-00198-7
Suzanne C O'Neill, Jada G Hamilton, Claire C Conley, Beth N Peshkin, Rosalba Sacca, Glynnis A McDonnell, Claudine Isaacs, Mark E Robson, Kenneth P Tercyak
{"title":"Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.","authors":"Suzanne C O'Neill, Jada G Hamilton, Claire C Conley, Beth N Peshkin, Rosalba Sacca, Glynnis A McDonnell, Claudine Isaacs, Mark E Robson, Kenneth P Tercyak","doi":"10.1186/s13053-021-00198-7","DOIUrl":"10.1186/s13053-021-00198-7","url":null,"abstract":"<p><p>Consensus and evidence suggest that cascade testing is critical to achieve the promise of cancer genetic testing. However, barriers to cascade testing include effective family communication of genetic risk information and family members' ability to cope with genetic risk. These barriers are further complicated by the developmental needs of unaffected family members during critical windows for family communication and adaptation. Peer support could address these barriers. We provide two illustrative examples of ongoing BRCA1/2-related clinical trials that apply a peer support model to improve family communication and functioning. Peer support can augment currently available genetic services to facilitate adjustment to and effective use of cancer genetic risk information. Importantly, this scalable approach can address the presence of cancer risk within families across multiple developmental stages. This applies a family-centered perspective that accommodates all potentially at-risk relatives. This peer support model can be further applied to emerging topics in clinical genetics to expand reach and impact.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"40"},"PeriodicalIF":1.7,"publicationDate":"2021-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39449629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Descriptive study on subjective experience of genetic testing with respect to relationship, family planning and psychosocial wellbeing among women with lynch syndrome. 对lynch综合征妇女在关系、计划生育和心理社会健康方面基因检测主观经验的描述性研究。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-09-14 DOI: 10.1186/s13053-021-00194-x
Mari Kalamo, Johanna Mäenpää, Toni Seppälä, Jukka-Pekka Mecklin, Kirsi Pylvänäinen, Synnöve Staff
{"title":"Descriptive study on subjective experience of genetic testing with respect to relationship, family planning and psychosocial wellbeing among women with lynch syndrome.","authors":"Mari Kalamo,&nbsp;Johanna Mäenpää,&nbsp;Toni Seppälä,&nbsp;Jukka-Pekka Mecklin,&nbsp;Kirsi Pylvänäinen,&nbsp;Synnöve Staff","doi":"10.1186/s13053-021-00194-x","DOIUrl":"https://doi.org/10.1186/s13053-021-00194-x","url":null,"abstract":"<p><strong>Background: </strong>Due to increased risk of endometrial and ovarian cancer, women belonging to known Lynch Syndrome (LS) families are recommended to undergo germline testing. Current practice in Finland is to offer counselling to women with pathogenic variant and advocate risk-reducing surgery (RRS) after completion of childbirth. The present study aimed to clarify the impacts of positive germline testing on family planning and reproductive decisions of these women, which are relatively unknown.</p><p><strong>Methods: </strong>Seventy-nine carriers of germline MMR gene pathogenic variant (path_MMR) were identified from the Finnish LS Registry as having genetic testing performed before the age of 45 years and not having undergone hysterectomy or oophorectomy. These women were sent a questionnaire concerning family planning, intimate relationships and psychosocial wellbeing.</p><p><strong>Results: </strong>Thirty-five women (44.3%) responded. Parity of path_MMR carriers (2.1) was slightly higher than parity among Finnish women in general (1.8). No significant differences were found between parity, number of induced abortions or sterilizations before and after genetic testing. Only minority of subjects reported any influence on family planning (20%) or negative impact on feminine self and body image (14%).</p><p><strong>Conclusions: </strong>The positive germline testing does not seem to have a major negative impact on family planning, intimate relationships or feminine self and body image. According to the open comments, counselling, supportive and empathic attitude of the professionals seem to have a significant impact on this. These results are a valuable addition to the counselling of LS women at reproductive age.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"38"},"PeriodicalIF":1.7,"publicationDate":"2021-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39417065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Correction to: Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. 更正:澳大利亚胰腺癌筛查项目参与者中新的生殖系致病变异的显著检测。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-09-08 DOI: 10.1186/s13053-021-00195-w
Krithika Murali, Tanya M Dwarte, Mehrdad Nikfarjam, Katherine M Tucker, Rhys B Vaughan, Marios Efthymiou, Allison Collins, Allan D Spigelman, Lucinda Salmon, Amber L Johns, David B Williams, Martin B Delatycki, Thomas John, Alina Stoita
{"title":"Correction to: Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.","authors":"Krithika Murali,&nbsp;Tanya M Dwarte,&nbsp;Mehrdad Nikfarjam,&nbsp;Katherine M Tucker,&nbsp;Rhys B Vaughan,&nbsp;Marios Efthymiou,&nbsp;Allison Collins,&nbsp;Allan D Spigelman,&nbsp;Lucinda Salmon,&nbsp;Amber L Johns,&nbsp;David B Williams,&nbsp;Martin B Delatycki,&nbsp;Thomas John,&nbsp;Alina Stoita","doi":"10.1186/s13053-021-00195-w","DOIUrl":"https://doi.org/10.1186/s13053-021-00195-w","url":null,"abstract":"","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"37"},"PeriodicalIF":1.7,"publicationDate":"2021-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427826/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39414270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations. 基于人群或家族史的乳腺癌BRCA基因检测?对经济评估的系统回顾。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-08-28 DOI: 10.1186/s13053-021-00191-0
Zahra Meshkani, Ali Aboutorabi, Najmeh Moradi, Mostafa Langarizadeh, Ali Ghanbari Motlagh
{"title":"Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations.","authors":"Zahra Meshkani,&nbsp;Ali Aboutorabi,&nbsp;Najmeh Moradi,&nbsp;Mostafa Langarizadeh,&nbsp;Ali Ghanbari Motlagh","doi":"10.1186/s13053-021-00191-0","DOIUrl":"10.1186/s13053-021-00191-0","url":null,"abstract":"<p><strong>Background: </strong>Nearly 56% of at-risk carriers are not identified and missed as a result of the current family-history (FH) screening for genetic testing. The present study aims to review the economic evaluation studies on BRCA genetic testing strategies for screening and early detection of breast cancer.</p><p><strong>Methods: </strong>This systematic literature review is conducted within the Cochrane Library, PubMed, Scopus, Web of Science, ProQuest, and EMBASE databases. In this paper, the relevant published economic evaluation studies are identified by following the standard Cochrane Collaboration methods and adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement reporting some recommendations for articles up to March 2020. Thereafter, the inclusion and exclusion criteria are applied to screen the articles. Disagreements are resolved through a consensus meeting. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist is used in the evaluation of quality. Finally, a narrative synthesis is performed. To compare the different levels of incremental cost-effectiveness ratio (ICER), the net present value is calculated based on a discount rate of 3% in 2019.</p><p><strong>Results: </strong>Among 788 initially retrieved citations, 12 studies were included. More than 60% of the studies were originated from high-income countries and were published after 2016. It is noteworthy that most of the studies evaluated the payer perspective. Moreover, the robustness of the results were analyzed through one-way and probabilistic sensitivity analyses in nearly 66% of these studies. Nearly, 25% of the studies are focused and defined population-based and family history BRCA tests as comparators; afterwards, the cost-effectiveness of the former was confirmed. The highest and lowest absolute values for the ICERs were $65,661 and $9 per quality adjusted life years, respectively. All studies met over 70% of the CHEERs criteria checklist, which was considered as 93% of high quality on average as well.</p><p><strong>Conclusions: </strong>The genetic BRCA tests for the general population as well as unselected breast cancer patients were cost-effective in high and upper-middle income countries and those with prevalence of gene mutation while population-based genetic tests for low-middle income countries are depended on the price of the tests.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"35"},"PeriodicalIF":1.7,"publicationDate":"2021-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39361987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Cytotoxic and targeted therapy for BRCA1/2-driven cancers. brca1 /2驱动癌症的细胞毒性和靶向治疗。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-08-28 DOI: 10.1186/s13053-021-00193-y
Evgeny N Imyanitov
{"title":"Cytotoxic and targeted therapy for BRCA1/2-driven cancers.","authors":"Evgeny N Imyanitov","doi":"10.1186/s13053-021-00193-y","DOIUrl":"https://doi.org/10.1186/s13053-021-00193-y","url":null,"abstract":"<p><p>Tumors arising in BRCA1/2 germline mutation carriers usually demonstrate somatic loss of the remaining BRCA1/2 allele and increased sensitivity to platinum compounds, anthracyclines, mitomycin C and poly (ADP-ribose) polymerase inhibitors (PARPi). Exposure to conventional platinum-based therapy or PARPi results in the restoration of BRCA1/2 function and development of resistance to systemic therapy, therefore, there is a need for other treatment options. Some studies suggested that the use of specific drug combinations or administration of high-dose chemotherapy may result in pronounced tumor responses. BRCA1/2-driven tumors are characterized by increased immunogenicity; promising efficacy of immune therapy has been demonstrated in a number of preclinical and clinical investigations. There are outstanding issues, which require further consideration. Platinum compounds and PARPi have very similar mode of antitumor action and are likely to render cross-resistance to each other, so their optimal position in cancer treatment schemes may be a subject of additional studies. Sporadic tumors with somatically acquired inactivation of BRCA1/2 or related genes resemble hereditary neoplasms with regard to the spectrum of drug sensitivity; the development of user-friendly BRCAness tests presents a challenge. Many therapeutic decisions are now based on the BRCA1/2 status, so the significant reduction of the turn-around time for predictive laboratory assays is of particular importance.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"36"},"PeriodicalIF":1.7,"publicationDate":"2021-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39362384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report. 黏液纤维肉瘤携带与Muir-Torre综合征相关的MLH1致病种系变异:1例报告。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-08-21 DOI: 10.1186/s13053-021-00192-z
Makoto Nakagawa, Eisuke Kobayashi, Masayoshi Yamada, Tomoko Watanabe, Makoto Hirata, Noriko Tanabe, Mineko Ushiama, Hiromi Sakamoto, Chiaki Sato, Taisuke Mori, Akihiko Yoshida, Teruhiko Yoshida, Kokichi Sugano, Akira Kawai
{"title":"Myxofibrosarcoma harboring an MLH1 pathogenic germline variant associated with Muir-Torre syndrome: a case report.","authors":"Makoto Nakagawa,&nbsp;Eisuke Kobayashi,&nbsp;Masayoshi Yamada,&nbsp;Tomoko Watanabe,&nbsp;Makoto Hirata,&nbsp;Noriko Tanabe,&nbsp;Mineko Ushiama,&nbsp;Hiromi Sakamoto,&nbsp;Chiaki Sato,&nbsp;Taisuke Mori,&nbsp;Akihiko Yoshida,&nbsp;Teruhiko Yoshida,&nbsp;Kokichi Sugano,&nbsp;Akira Kawai","doi":"10.1186/s13053-021-00192-z","DOIUrl":"https://doi.org/10.1186/s13053-021-00192-z","url":null,"abstract":"<p><strong>Background: </strong>Muir-Torre syndrome (MTS), which accounts for a small subset (1-3 %) of Lynch syndrome (LS), is an autosomal dominant genetic disorder characterized by sebaceous gland or keratoacanthoma associated with visceral malignancies. Most families with MTS have pathogenic germline variants (PGV) in MSH2. Sarcomas are not common on the LS tumor spectrum, and sarcomas associated with MTS are extremely rare.</p><p><strong>Case presentation: </strong>Here we report a myxofibrosarcoma of the abdominal wall in a 73-year-old man with a sebaceoma that occurred synchronically, leading to a diagnosis of MTS. The loss of MLH1 and PMS2 protein expression was detected in immunohistochemistry, and high-frequency microsatellite instability (MSI-H) was also confirmed. A germline genetic analysis revealed that he harbored the MLH1 PGV.</p><p><strong>Conclusions: </strong>This is the first case of MSI-H myxofibrosarcoma with MTS in an MLH1 PGV carrier. Although rare, we should recognize that sarcomas can be part of the spectrum of LS and MTS.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"34"},"PeriodicalIF":1.7,"publicationDate":"2021-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39332205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants. 澳大利亚胰腺癌筛查项目参与者中新的生殖系致病变异的显著检测。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-08-16 DOI: 10.1186/s13053-021-00190-1
Krithika Murali, Tanya M Dwarte, Mehrdad Nikfarjam, Katherine M Tucker, Rhys B Vaughan, Marios Efthymiou, Allison Collins, Allan D Spigelman, Lucinda Salmon, Amber L Johns, David B Williams, Martin B Delatycki, Thomas John, Alina Stoita
{"title":"Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants.","authors":"Krithika Murali,&nbsp;Tanya M Dwarte,&nbsp;Mehrdad Nikfarjam,&nbsp;Katherine M Tucker,&nbsp;Rhys B Vaughan,&nbsp;Marios Efthymiou,&nbsp;Allison Collins,&nbsp;Allan D Spigelman,&nbsp;Lucinda Salmon,&nbsp;Amber L Johns,&nbsp;David B Williams,&nbsp;Martin B Delatycki,&nbsp;Thomas John,&nbsp;Alina Stoita","doi":"10.1186/s13053-021-00190-1","DOIUrl":"10.1186/s13053-021-00190-1","url":null,"abstract":"<p><strong>Background: </strong>The Australian Pancreatic Cancer Screening Program (APCSP) offers endoscopic ultrasound surveillance for individuals at increased risk of pancreatic ductal adenocarcinoma (PDAC) with all participants requiring assessment by a Familial Cancer Service before or after study enrolment.</p><p><strong>Methods: </strong>Individuals aged 40-80 years (or 10 years younger than the earliest PDAC diagnosis) were eligible for APCSP study entry if they had 1) ≥ two blood relatives with PDAC (at least one of first-degree association); 2) a clinical or genetic diagnosis of Hereditary Pancreatitis or Peutz-Jeghers syndrome irrespective of PDAC family history; or 3) a known PDAC predisposition germline pathogenic variant (BRCA2, PALB2, CDKN2A, or Lynch syndrome) with ≥one PDAC-affected first- or second-degree relative. Retrospective medical record review was conducted for APCSP participants enrolled at the participating Australian hospitals from January 2011 to December 2019. We audited the genetic investigations offered by multiple Familial Cancer Services who assessed APCSP participants according to national guidelines, local clinical protocol and/or the availability of external research-funded testing, and the subsequent findings. Descriptive statistical analysis was performed using Microsoft Excel.</p><p><strong>Results: </strong>Of 189 kindreds (285 participants), 50 kindreds (71 participants) had a known germline pathogenic variant at enrolment (BRCA2 n = 35, PALB2 n = 6, CDKN2A n = 3, STK11 n = 3, PRSS1 n = 2, MLH1 n = 1). Forty-eight of 136 (35%) kindreds with no known germline pathogenic variant were offered mutation analysis; 89% was clinic-funded, with increasing self-funded testing since 2016. The relatively low rates of genetic testing performed reflects initial strict criteria for clinic-funded genetic testing. New germline pathogenic variants were detected in five kindreds (10.4%) after study enrolment (BRCA2 n = 3 kindreds, PALB2 n = 1, CDKN2A n = 1). Of note, only eight kindreds were reassessed by a Familial Cancer Service since enrolment, with a further 21 kindreds identified as being suitable for reassessment.</p><p><strong>Conclusion: </strong>Germline pathogenic variants associated with PDAC were seen in 29.1% of our high-risk cohort (55/189 kindreds; 82/285 participants). Importantly, 10.4% of kindreds offered genetic testing were newly identified as having germline pathogenic variants, with majority being BRCA2. As genetic testing standards evolve rapidly in PDAC, 5-yearly reassessment of high-risk individuals by Familial Cancer Services is warranted.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"33"},"PeriodicalIF":1.7,"publicationDate":"2021-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39329156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature. 扩展E318K (c.952G > A) MITF种系突变携带者的表型:病例系列和文献综述
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-07-21 DOI: 10.1186/s13053-021-00189-8
Leandro Jonata Carvalho Oliveira, Aline Bobato Lara Gongora, Fabiola Ambrosio Silveira Lima, Felipe Sales Nogueira Amorim Canedo, Carla Vanessa Quirino, Janina Pontes Pisani, Maria Isabel Achatz, Benedito Mauro Rossi
{"title":"Expanding the phenotype of E318K (c.952G > A) MITF germline mutation carriers: case series and review of the literature.","authors":"Leandro Jonata Carvalho Oliveira,&nbsp;Aline Bobato Lara Gongora,&nbsp;Fabiola Ambrosio Silveira Lima,&nbsp;Felipe Sales Nogueira Amorim Canedo,&nbsp;Carla Vanessa Quirino,&nbsp;Janina Pontes Pisani,&nbsp;Maria Isabel Achatz,&nbsp;Benedito Mauro Rossi","doi":"10.1186/s13053-021-00189-8","DOIUrl":"https://doi.org/10.1186/s13053-021-00189-8","url":null,"abstract":"<p><strong>Background: </strong>The microphthalmia-associated transcription factor gene (MITF) belongs to the MYC supergene family and plays an important role in melanocytes' homeostasis. Individuals harboring MITF germline pathogenic variants are at increased risk of developing cancer, most notably melanoma and renal cell carcinoma.</p><p><strong>Case presentation: </strong>We describe a cohort of ten individuals who harbor the same MITF c.952G > A (p.Glu 318Lys), or p.E318K, germline pathogenic variant. Six carriers developed at least one malignancy (4 cases of breast cancer; 1 cervical cancer; 1 colon cancer; 1 melanoma; 1 ovarian/fallopian tube cancer). A significant phenotypic heterogeneity was found among these individuals and their relatives. Breast cancer was, overall, the most frequent malignancy observed in this case series, with 13 occurrences of 60 (21.67 %) total cancer cases described among the probands and their relatives.</p><p><strong>Conclusions: </strong>Our retrospective analysis data raise the hypothesis of a possible association of the MITF p.E318K pathogenic variant with an increased risk of breast cancer.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"32"},"PeriodicalIF":1.7,"publicationDate":"2021-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13053-021-00189-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39206357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation and comparison of hereditary Cancer guidelines in the population. 评估和比较人群中的遗传性癌症指南。
IF 1.7 4区 医学
Hereditary Cancer in Clinical Practice Pub Date : 2021-07-17 DOI: 10.1186/s13053-021-00188-9
Jordon B Ritchie, Cecelia Bellcross, Caitlin G Allen, Lewis Frey, Heath Morrison, Joshua D Schiffman, Brandon M Welch
{"title":"Evaluation and comparison of hereditary Cancer guidelines in the population.","authors":"Jordon B Ritchie, Cecelia Bellcross, Caitlin G Allen, Lewis Frey, Heath Morrison, Joshua D Schiffman, Brandon M Welch","doi":"10.1186/s13053-021-00188-9","DOIUrl":"10.1186/s13053-021-00188-9","url":null,"abstract":"<p><strong>Background: </strong>Family health history (FHx) is an effective tool for identifying patients at risk of hereditary cancer. Hereditary cancer clinical practice guidelines (CPG) contain criteria used to evaluate FHx and to make recommendations for genetic consultation. Comparing different CPGs used to evaluate a common set of FHx provides insight into how well the CPGs perform, the extent of agreement across guidelines, and how well they identify patients who should consider a cancer genetic consultation.</p><p><strong>Methods: </strong>We compare the American College of Medical Genetics and Genomics (ACMG) and the National Comprehensive Cancer Networks (NCCN) (2019) CPG criteria for FHx collected by a chatbot and evaluated by ontologies and web services in a previous study. Collected FHx met criteria from seven groups: Gene Mutation, Breast and Ovarian, Li-Fraumeni syndrome (LFS), Colorectal and Endometrial, Relative Meets Criteria, ACMG Only Criteria, and NCCN Testing. CPG Criteria were coded and matched across 12 ACMG sub-guidelines and 6 NCCN sub-guidelines for comparison purposes.</p><p><strong>Results: </strong>The dataset contains 4915 records, of which 2221 met either ACMG or NCCN criteria and 2694 did not. There was significant overlap-1179 probands met both ACMG and NCCN criteria. The greatest similarities were for Gene Mutation and Breast and Ovarian criteria and the greatest disparity existed among Colorectal and Endometrial criteria. Only 156 positive gene mutations were reported and of the 2694 probands who did not meet criteria, 90.6% of them reported at least one cancer in their personal or family cancer history.</p><p><strong>Conclusion: </strong>Hereditary cancer CPGs are useful for identifying patients at risk of developing cancer based on FHx. This comparison shows that with the aid of chatbots, ontologies, and web services, CPGs can be more efficiently applied to identify patients at risk of hereditary cancer. Additionally this comparison examines similarities and differences between ACMG and NCCN and shows the importance of using both guidelines when evaluating hereditary cancer risk.</p>","PeriodicalId":55058,"journal":{"name":"Hereditary Cancer in Clinical Practice","volume":"19 1","pages":"31"},"PeriodicalIF":1.7,"publicationDate":"2021-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39193649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信